吲哚胺2,3-双加氧酶
医学
免疫疗法
临床试验
癌症
化疗
恶性肿瘤
癌症免疫疗法
药理学
肿瘤科
免疫学
内科学
生物
生物化学
氨基酸
色氨酸
作者
Sarah Yentz,David Smith
出处
期刊:BioDrugs
[Springer Nature]
日期:2018-07-06
卷期号:32 (4): 311-317
被引量:57
标识
DOI:10.1007/s40259-018-0291-4
摘要
Indoleamine 2,3-dioxygenase (IDO) is an enzyme of interest in immuno-oncology because of the immunosuppressive effects that result from its role in tryptophan catabolism. IDO is upregulated in malignancy and is associated with poor prognosis in multiple cancer types. IDO inhibitors have been developed to target IDO, both directly and indirectly. Pre-clinical data have shown combined IDO and checkpoint inhibition to be an efficacious strategy for tumor control. Clinical trials of IDO inhibitors with chemotherapy or immunotherapy are currently underway. This review describes the function of IDO and its inhibitors and summarizes the efficacy and toxicity data from recent clinical trials with these drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI